Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Earth Science TechETST +9.29%36 Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus rates ETST with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Earth Science Tech ranks better than 99.88% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Earth Science Tech's Debt-to-Equity or its related term are showing as below:
ETST'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.98 Med: -0.06 Max: 6.67
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Earth Science Tech was 6.67. The lowest was -0.98. And the median was -0.06.
ETST's Debt-to-Equity is ranked better than 99.88% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ETST: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Earth Science Tech Debt-to-Equity Related Terms
Earth Science Tech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Earth Science Tech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ETST vs IXHL, SCYX, INIS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Earth Science Tech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Earth Science Tech Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Earth Science Tech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Earth Science Tech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Earth Science Tech (ETST) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Earth Science Tech and its competitors. According to the industry distribution chart, Earth Science Tech ranks #1 out of 813 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Earth Science Tech's Debt-to-Equity too high?
Earth Science Tech's current Debt-to-Equity is 0.01. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Earth Science Tech's value of 0.01 is 96.3% below this industry median. Based on the distribution chart, Earth Science Tech ranks #1 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Earth Science Tech has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Earth Science Tech's Debt-to-Equity compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, Earth Science Tech ranks #1 out of 813 companies for Debt-to-Equity. This places Earth Science Tech in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Earth Science Tech's value of 0.01 is 96.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Earth Science Tech's current Debt-to-Equity of 0.01 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Earth Science Tech and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Earth Science Tech's current Debt-to-Equity is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Earth Science Tech stock overvalued right now?
Earth Science Tech (ETST) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01 and 96.3% below the Drug Manufacturers industry median of 0.27. Earth Science Tech's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Earth Science Tech (ETST), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Earth Science Tech Inc is a diversified holding company. The company focuses on the health and wellness sector. The Company's principal operating plan is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the Company's value proposition is the seamless integration of patient care, from consultation to fulfillment.
36GF Score
Get the complete analysis for ETST
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ETST has been successfully added to your 
